R. Adam, V. Delvart, G. Pascal, A. Valeanu, D. Castaing et al., Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival, Ann. Surg, vol.240, pp.644-657, 2004.

T. Delaunoit, S. R. Alberts, D. J. Sargent, E. Green, R. M. Goldberg et al., Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741, Ann. Oncol, vol.16, pp.425-429, 2005.

A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini et al., Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The gruppo oncologico nord ovest, J. Clin. Oncol, vol.25, pp.1670-1676, 2007.

M. Ychou, M. Rivoire, S. Thezenas, R. Guimbaud, F. Ghiringhelli et al., FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study-Prodige 14-ACCORD 21 (METHEP-2), a unicancer GI trial, J. Clin. Oncol, vol.34, p.3512, 2016.

S. J. Cohen, C. J. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath et al., Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer, J. Clin. Oncol, vol.26, pp.3213-3221, 2008.

J. Sastre, M. Vidaurreta, A. Gómez, F. Rivera, B. Massutí et al., Prognostic value of the combination of circulating tumor cells plus kras in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab, Clin. Colorectal Cancer, vol.12, pp.280-286, 2013.

J. Tol, M. Koopman, M. C. Miller, A. Tibbe, A. Cats et al., Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents, Ann. Oncol, vol.21, pp.1006-1012, 2010.

X. Huang, P. Gao, Y. Song, J. Sun, X. Chen et al., Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer, BMC Cancer, vol.15, p.202, 2015.

F. C. Bidard, F. Huguet, C. Louvet, L. Mineur, O. Bouche et al., Circulating tumor cells in locally advanced pancreatic adenocarcinoma: The ancillary CirCe 07 study to the LAP 07 trial, Ann. Oncol, vol.24, pp.2057-2061, 2013.

F. C. Bidard, F. R. Ferrand, F. Huguet, P. Hammel, C. Louvet et al., Disseminated and circulating tumor cells in gastrointestinal oncology, Crit. Rev. Oncol. Hematol, vol.82, pp.103-115, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00711407

F. Bidard, B. Weigelt, and J. S. Reis-filho, Going with the flow: From circulating tumor cells to DNA, Sci. Transl. Med, 2013.

J. Douillard, G. Ostoros, M. Cobo, T. Ciuleanu, R. Cole et al., Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor dna as a surrogate for determination of egfr status, J. Thorac. Oncol, vol.9, pp.1345-1353, 2014.

A. R. Thierry, F. Mouliere, S. El-messaoudi, C. Mollevi, E. Lopez-crapez et al., Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat. Med, vol.20, pp.430-435, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168071

G. Siravegna, B. Mussolin, M. Buscarino, G. Corti, A. Cassingena et al., Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat. Med, vol.795, 2015.

J. Tabernero, H. Lenz, S. Siena, A. Sobrero, A. Falcone et al., Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: A retrospective, exploratory analysis of the CORRECT trial, Lancet Oncol, vol.16, pp.937-948, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02326053

C. Raimondi, C. Nicolazzo, F. Belardinilli, F. Loreni, A. Gradilone et al., Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer, Cancers, vol.11, p.42, 2019.

F. Diehl, K. Schmidt, M. A. Choti, K. Romans, S. Goodman et al., Circulating mutant DNA to assess tumor dynamics, Nat. Med, vol.14, pp.985-990, 2008.

J. Tie, I. Kinde, Y. Wang, H. L. Wong, J. Roebert et al., Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann. Oncol, vol.26, pp.1715-1722, 2015.

J. Tie, Y. Wang, C. Tomasetti, L. Li, S. Springer et al., Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage, II colon cancer. Sci. Transl. Med, vol.8, 2016.

M. Ychou, M. Rivoire, S. Thezenas, F. Quenet, J. Delpero et al., A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial, Ann. Surg. Oncol, vol.20, pp.4289-4297, 2013.

W. J. Allard, Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases, Clin. Cancer Res, vol.10, pp.6897-6904, 2004.

R. Lebofsky, C. Decraene, V. Bernard, M. Kamal, A. Blin et al., Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types, Mol. Oncol, vol.9, pp.783-790, 2015.

J. Madic, A. Kiialainen, F. Bidard, F. Birzele, G. Ramey et al., Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients: ctDNA and CTC in metastatic triple negative breast cancer, Int. J. Cancer, vol.136, pp.2158-2165, 2015.

J. B. Bachet, O. Bouché, J. Taieb, O. Dubreuil, M. L. Garcia et al., RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: The AGEO RASANC prospective multicenter study, Ann. Oncol, vol.29, pp.1211-1219, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02332812

N. Pécuchet, E. Zonta, A. Didelot, P. Combe, C. Thibault et al., Base-position error rate analysis of next-generation sequencing applied to circulating tumor dna in non-small cell lung cancer: A prospective study, PLoS Med, vol.13, p.1002199, 2016.

C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang et al., Detection of circulating tumor dna in early-and late-stage human malignancies, Sci. Transl. Med, 2014.

R. R. Narayan, D. A. Goldman, M. Gonen, J. Reichel, K. H. Huberman et al., Peripheral circulating tumor dna detection predicts poor outcomes after liver resection for metastatic colorectal cancer, Ann. Surg. Oncol, vol.26, pp.1824-1832, 2019.

J. Tie, J. Cohen, Y. Wang, M. Lee, R. Wong et al., Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC), J. Clin. Oncol, vol.36, p.3516, 2018.

F. Garlan, P. Laurent-puig, D. Sefrioui, N. Siauve, A. Didelot et al., Early evaluation of circulating tumor dna as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL Study), Clin. Cancer Res, vol.23, pp.5416-5425, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02353169

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, D. Le-corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin. Chem, vol.59, pp.1722-1731, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02332865

C. Decraene, A. B. Silveira, F. Bidard, A. Vallée, M. Michel et al., Multiple hotspot mutations scanning by single droplet digital PCR, Clin. Chem, vol.64, pp.317-328, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01823628

S. Garrigou, G. Perkins, F. Garlan, C. Normand, A. Didelot et al., A Study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker, Clin. Chem, vol.62, pp.1129-1139, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02295782

F. Bidard, J. Madic, P. Mariani, S. Piperno-neumann, A. Rampanou et al., Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma: Circulating tumor DNA in uveal melanoma, Int. J. Cancer, vol.134, pp.1207-1213, 2014.

M. M. Ferreira, V. C. Ramani, and S. S. Jeffrey, Circulating tumor cell technologies, Mol. Oncol, vol.10, pp.374-394, 2016.

A. Saliba, L. Saias, E. Psychari, N. Minc, D. Simon et al., Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays, Proc. Natl. Acad. Sci, vol.107, pp.14524-14529, 2010.

P. Kuhn, S. Keating, G. Baxter, K. Thomas, A. Kolatkar et al., Lessons learned: Transfer of the high-definition circulating tumor cell assay platform to development as a commercialized clinical assay platform, Clin. Pharmacol. Ther, vol.102, pp.777-785, 2017.

K. C. Andree, A. Mentink, L. L. Zeune, L. W. Terstappen, N. H. Stoecklein et al., Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap): Toward a real liquid biopsy in metastatic breast and prostate cancer, Int. J. Cancer, vol.143, pp.2584-2591, 2018.

V. Vsiansky, M. Svobodova, J. Gumulec, N. Cernei, D. Sterbova et al., Prognostic significance of serum free amino acids in head and neck cancers, Cells, vol.8, p.428, 2019.

M. Giussani, T. Triulzi, G. Sozzi, and E. Tagliabue, Tumor extracellular matrix remodeling: new perspectives as a circulating tool in the diagnosis and prognosis of solid tumors, vol.8, p.81, 2019.